5Lang A E, Melamed E, Poewe W, et al. Trim designs used to study neuroprotective therapy in Parkinos's disease[ J]. Mov Disord, 2013 ( 28 ) : 86 ~ 95.
6Clarke C E, Patel S, Ives N, et al. Should treatment for Parkin- son's disease start immediately on diagnosis of delayed until functional disability develops? [ J ]. Mov Disord, 2011 ( 26 ) : 1187 ~ 1193.
7Gazewood J D, Richards D R, Clebak K. Parkinson disease: an update [ J ]. Am Fam Physician,2013 ( 87 ) : 267 ~ 273.
8Mcghee D J, Royle P L, Thompson P A, et al. A systematic review of biomarkers for disease progression in Parkinson's disease[ J]. BMC Neurol,2013 ( 13 ) :35.
9VILES JH. Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper, Zinc and Iron in Alzheimer" s,Parkinson's and priori diseases [ J ]. Coord Chem Rev, 2012, 256 (19/20) :2271 - 2284.
10ZHENG W, MONNOT AD. Regulation of brain Iron and Copper homeostasis by brain barrier systems : implication in neurodegenerative diseases [ J ]. Pharmacol Ther, 2012, 133 (2) : 177 - 188.
